Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.57 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.56 |
| ▸ | KRAS | P01116 | 2/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19448916 | 1.00 | TGM2 (0.61) | TGM2FUT5NT5EP2RY2P2RY4 | |
| SCHEMBL19185923 | 0.94 | TGM2 (0.57) | TGM2FUT5NT5EP2RY2P2RY4 | |
| SCHEMBL25552773 | 0.94 | TGM2 (0.60) | TGM2FUT5NT5EP2RY2P2RY4 | |
| SCHEMBL18937285 | 0.94 | FUT5 (0.55) | TGM2FUT5NT5EP2RY2P2RY4 | |
| SCHEMBL22142885 | 0.93 | TGM2 (0.57) | TGM2FUT5NT5EP2RY2P2RY4 | |
| SCHEMBL18320601 | 0.91 | NT5E (0.72) | TGM2FUT5NT5EP2RY2P2RY4 | |
| SCHEMBL23477028 | 0.90 | FUT5 (0.58) | TGM2FUT5NT5EP2RY2P2RY4 | |
| SCHEMBL19186042 | 0.90 | RNASEL (0.69) | RNASEL | |
| SCHEMBL18937290 | 0.90 | RNASEL (0.69) | RNASEL | |
| SCHEMBL23477159 | 0.90 | RNASEL (0.56) | TGM2FUT5RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200330556-A1 | Methods for Administering STING Agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| EP-3440072-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330556-A1 | Methods for Administering STING Agonists | STING1, CGAS, TLR9 | TGM2 3197/4885FUT5 4061/4885NT5E 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.